Suppr超能文献

主观认知衰退与tau蛋白病的区域特异性关联,独立于整体β-淀粉样蛋白负荷。

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.

作者信息

Buckley Rachel F, Hanseeuw Bernard, Schultz Aaron P, Vannini Patrizia, Aghjayan Sarah L, Properzi Michael J, Jackson Jonathan D, Mormino Elizabeth C, Rentz Dorene M, Sperling Reisa A, Johnson Keith A, Amariglio Rebecca E

机构信息

Florey Institutes of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia.

Melbourne School of Psychological Science, University of Melbourne, Australia.

出版信息

JAMA Neurol. 2017 Dec 1;74(12):1455-1463. doi: 10.1001/jamaneurol.2017.2216.

Abstract

IMPORTANCE

The ability to explore associations between reports of subjective cognitive decline (SCD) and biomarkers of early Alzheimer disease (AD) pathophysiologic processes (accumulation of neocortical β-amyloid [Aβ] and tau) provides an important opportunity to understand the basis of SCD and AD risk.

OBJECTIVE

To examine associations between SCD and global Aβ and tau burdens in regions of interest in clinically healthy older adults.

DESIGN, SETTING, AND PARTICIPANTS: This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ. The following 2 regions for tau burden were identified: the entorhinal cortex, which exhibits early signs of tauopathy, and the inferior temporal region, which is more closely associated with AD-related pathologic mechanisms. Data were collected from June 11, 2012, through April 7, 2016.

MAIN OUTCOMES AND MEASURES

Subjective cognitive decline was measured using a previously published method of z-transforming subscales from the Memory Functioning Questionnaire, the Everyday Cognition battery, and a 7-item questionnaire. The Aβ level was measured according to a summary distribution volume ratio of frontal, lateral temporal and parietal, and retrosplenial PiB-PET tracer uptake. The FTP-PET measures were computed as standardized uptake value ratios. Linear regression models focused on main and interactive effects of Aβ, entorhinal cortical, and inferior temporal tau on SCD, controlling for age, sex, educational attainment, and Geriatric Depression Scale score.

RESULTS

Of the 133 participants, 75 (56.3%) were women and 58 (43.6%) were men; mean (SD) age was 76 (6.9) years (range, 55-90 years). Thirty-nine participants (29.3%) exhibited a high Aβ burden. Greater SCD was associated with increasing entorhinal cortical tau burden (β = 0.35; 95% CI, 0.19-.52; P < .001) and Aβ burden (β = 0.24; 95% CI, 0.08-.40; P = .005), but not inferior temporal tau burden (β = 0.10; 95% CI, -0.08 to 0.28; P = .27). This association between entorhinal cortical tau burden and SCD was largely unchanged after accounting for Aβ burden (β = 0.36; 95% CI, 0.15-.58; P = .001), and no interaction influenced SCD (β = -0.36; 95% CI, -0.34 to 0.09; P = .25). An exploratory post hoc whole-brain analysis also indicated that SCD was predominantly associated with greater tau burden in the entorhinal cortex.

CONCLUSIONS AND RELEVANCE

Subjective cognitive decline is indicative of accumulation of early tauopathy in the medial temporal lobe, specifically in the entorhinal cortex, and to a lesser extent, elevated global levels of Aβ. Our findings suggest multiple underlying pathways that motivate SCD that do not necessarily interact to influence SCD endorsement. As such, multiple biological factors must be considered when assessing SCD in clinically healthy older adults.

摘要

重要性

探究主观认知下降(SCD)报告与早期阿尔茨海默病(AD)病理生理过程生物标志物(新皮质β-淀粉样蛋白[Aβ]和tau蛋白积累)之间的关联,为理解SCD和AD风险的基础提供了重要契机。

目的

研究临床健康老年人中SCD与感兴趣区域的整体Aβ和tau蛋白负荷之间的关联。

设计、地点和参与者:这项哈佛衰老大脑研究的影像学子研究纳入了133名临床健康的老年参与者(临床痴呆评定量表整体评分为0),他们参与了哈佛衰老大脑研究,接受了横断面氟代托品F 18(以前称为AV 1451、T807)正电子发射断层扫描(FTP-PET)成像以检测tau蛋白,以及匹兹堡化合物B碳11标记的PET(PiB-PET)成像以检测Aβ。确定了以下2个tau蛋白负荷区域:内嗅皮质,其表现出tau蛋白病的早期迹象;颞下区域,其与AD相关病理机制联系更为紧密。数据收集时间为2012年6月11日至2016年4月7日。

主要结局和测量指标

使用先前发表的方法,对记忆功能问卷、日常认知量表的分量表以及一份7项问卷进行z变换来测量主观认知下降。根据额叶、颞叶外侧和顶叶以及压后皮质PiB-PET示踪剂摄取的汇总分布体积比来测量Aβ水平。FTP-PET测量值计算为标准化摄取值比率。线性回归模型重点关注Aβ、内嗅皮质和颞下tau蛋白对SCD的主要和交互作用,同时控制年龄、性别、教育程度和老年抑郁量表评分。

结果

133名参与者中,75名(56.3%)为女性,58名(43.6%)为男性;平均(标准差)年龄为76(6.9)岁(范围为55 - 90岁)。39名参与者(29.3%)表现出高Aβ负荷。SCD增加与内嗅皮质tau蛋白负荷增加(β = 0.35;95%置信区间,0.19 - 0.52;P < 0.001)和Aβ负荷增加(β = 0.24;95%置信区间,0.08 - 0.40;P = 0.005)相关,但与颞下tau蛋白负荷无关(β = 0.10;95%置信区间,-0.08至0.28;P = 0.27)。在考虑Aβ负荷后,内嗅皮质tau蛋白负荷与SCD之间的这种关联基本不变(β = 0.36;95%置信区间,0.15 - 0.58;P = 0.001),且没有交互作用影响SCD(β = -0.36;95%置信区间,-0.34至0.09;P = 当考虑Aβ负荷后,内嗅皮质tau负担与SCD之间的这种关联基本不变(β = 0.36;95%置信区间,0.15 - 0.58;P = 0.001),且没有交互作用影响SCD(β = -0.36;95%置信区间,-0.34至0.09;P = 0.25)。一项探索性的事后全脑分析还表明,SCD主要与内嗅皮质中更大的tau负担相关。

结论与意义

主观认知下降表明内侧颞叶,特别是内嗅皮质中早期tau蛋白病的积累,以及在较小程度上,整体Aβ水平升高。我们的研究结果提示了多种导致SCD的潜在途径,这些途径不一定相互作用来影响SCD的认可情况。因此,在评估临床健康老年人的SCD时,必须考虑多种生物学因素。

相似文献

1
3
Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.
JAMA Neurol. 2016 Oct 1;73(10):1185-1191. doi: 10.1001/jamaneurol.2016.2237.
4
Association of and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.
Neurology. 2021 Feb 2;96(5):e650-e661. doi: 10.1212/WNL.0000000000011270. Epub 2020 Dec 1.
6
Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
JAMA Neurol. 2018 May 1;75(5):548-556. doi: 10.1001/jamaneurol.2017.4907.
7
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
JAMA Neurol. 2016 Nov 1;73(11):1334-1341. doi: 10.1001/jamaneurol.2016.3338.
8
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.
9
Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau.
Ann Neurol. 2019 Feb;85(2):272-279. doi: 10.1002/ana.25399. Epub 2019 Jan 7.

引用本文的文献

1
Path integration impairments reveal early cognitive changes in subjective cognitive decline.
Sci Adv. 2025 Sep 5;11(36):eadw6404. doi: 10.1126/sciadv.adw6404. Epub 2025 Sep 3.
2
Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints.
Alzheimers Dement (Amst). 2025 Aug 28;17(3):e70176. doi: 10.1002/dad2.70176. eCollection 2025 Jul-Sep.
3
Disease stage-specific atrophy markers in Alzheimer's disease.
Alzheimers Dement. 2025 Jul;21(7):e70482. doi: 10.1002/alz.70482.
4
The Potential for Neuromodulation in the Treatment of Alzheimer's Disease: A Review of Clinical Trials.
Cureus. 2025 May 31;17(5):e85156. doi: 10.7759/cureus.85156. eCollection 2025 May.
5
Association of item-level responses to cognitive function index with tau pathology and hippocampal volume in the A4 Study.
Alzheimers Dement (Amst). 2025 Jun 18;17(2):e70128. doi: 10.1002/dad2.70128. eCollection 2025 Apr-Jun.
6
Vascular risk factor associations with subjective cognitive decline and mild behavioural impairment.
Brain Commun. 2025 Apr 28;7(3):fcaf163. doi: 10.1093/braincomms/fcaf163. eCollection 2025.
7
Loneliness and biomarkers of brain pathology in people with subjective cognitive decline.
Sci Rep. 2025 Apr 2;15(1):11299. doi: 10.1038/s41598-025-95411-1.
8
Disease stage-specific atrophy markers in Alzheimer's disease.
medRxiv. 2025 Mar 14:2025.03.13.25323904. doi: 10.1101/2025.03.13.25323904.
9
Path integration impairments reveal early cognitive changes in Subjective Cognitive Decline.
bioRxiv. 2025 Feb 18:2025.02.17.638583. doi: 10.1101/2025.02.17.638583.
10
SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.
Alzheimers Dement. 2025 May;21(5):e14307. doi: 10.1002/alz.14307. Epub 2025 Feb 22.

本文引用的文献

1
Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline.
Ann Neurol. 2017 Apr;81(4):583-596. doi: 10.1002/ana.24910. Epub 2017 Apr 6.
2
Implementation of subjective cognitive decline criteria in research studies.
Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012. Epub 2016 Nov 5.
3
Subjective Cognitive Impairment and Affective Symptoms: A Systematic Review.
Gerontologist. 2016 Dec;56(6):e109-e127. doi: 10.1093/geront/gnw091. Epub 2016 Jun 23.
4
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Brain. 2016 May;139(Pt 5):1551-67. doi: 10.1093/brain/aww027. Epub 2016 Mar 8.
5
PET Imaging of Tau Deposition in the Aging Human Brain.
Neuron. 2016 Mar 2;89(5):971-982. doi: 10.1016/j.neuron.2016.01.028.
6
Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging.
Neuroimage. 2016 May 15;132:334-343. doi: 10.1016/j.neuroimage.2016.02.042. Epub 2016 Feb 23.
7
Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease.
Alzheimers Dement. 2016 Jul;12(7):796-804. doi: 10.1016/j.jalz.2015.12.013. Epub 2016 Feb 4.
8
Tau positron emission tomographic imaging in aging and early Alzheimer disease.
Ann Neurol. 2016 Jan;79(1):110-9. doi: 10.1002/ana.24546. Epub 2015 Dec 15.
9
Amyloid and Tau Biomarkers in Subjective Cognitive Impairment.
J Alzheimers Dis. 2015;47(1):1-8. doi: 10.3233/JAD-150180.
10
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.
Curr Opin Neurobiol. 2016 Feb;36:43-51. doi: 10.1016/j.conb.2015.09.002. Epub 2015 Sep 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验